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AutologousThe range of possible gene and cell therapy applications is expanding at an extremely rapid rate and advanced
therapymedicinal products (ATMPs) are currently the hottest topic in novel medicines, particularly for inherited
diseases. Paediatric patients stand to gain enormously from these novel therapies as it now seems plausible to
develop a gene or cell therapy for a vast number of inherited diseases.
There are a wide variety of potential gene and cell therapies in various stages of development. Patients who re-
ceived ﬁrst gene therapy treatments for primary immune deﬁciencies (PIDs) are reaching 10 and 15 years post-
treatment, with robust and sustained immune recovery. Cell therapy clinical trials are underway for a variety of
tissues including corneal, retinal andmuscle repair and islet cell transplantation. Various cell therapy approaches
are also being trialled to enhance the safety of bone marrow transplants, which should improve survival rates in
childhood cancers and PIDs. Progress in genetic engineering of lymphocyte populations to target and kill cancer-
ous cells is also described. If successful these ATMPsmay enhance or replace the existing chemo-ablative therapy
for several paediatric cancers. Emerging applications of gene therapy now include skin andneurological disorders
such as epidermolysis bullosa, epilepsy and leukodystrophy. Gene therapy trials for haemophilia, muscular dys-
trophy and a range of metabolic disorders are underway. There is a vast array of potential advanced therapyme-
dicinal products (ATMPs), and these are likely to be more cost effective than existing medicines. However, the
ﬁrst clinical trials havenot beenwithout setbacks and some of the key adverse events are discussed. Furthermore,
the arrival of this novel class of therapies brings many new challenges for the healthcare industry. We present a
summary of the key non-clinical factors required for successful delivery of these potential treatments. Technolog-
ical advances are needed in vector design, rawmaterial manufacture, cell culture and transductionmethodology,
and particularly in making all these technologies readily scalable.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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1.1. Introduction
We are currently undergoing a technological revolution inmedicine.
The elucidation of the human genome and the development of high
throughput gene sequencing technologies have led to the rapid under-
standing of the genetic basis of many inherited diseases. We have also
seen remarkable technological advances in gene transfer and cell ma-
nipulation and culture, which enable speciﬁc engineering of both
human stem cells and terminally differentiated cell populations for
many applications. These developments are leading to new therapeutic
options for a wide range of inherited and acquired conditions and have
challenged our conventional view of ‘medicines’. However, at present,
both cell and gene modiﬁed cell therapies have almost exclusively
been developed and used in the academic environment. Their transla-
tion is presently occurring in basic research centres, under compassion-
ate use schemes or in approved hospital-based clinical trials (see Fig. 1).
The co-localisation of clinicians, patients and scientists where partner-
ships exist between a university and a hospital has been fundamental
especially in rare diseases tomoving directly to testing in patient groups
(Phase I/II clinical trials) without ﬁrst testing in healthy human volun-
teers (Phase I clinical trials). However as we approach 20 years since
the ﬁrst clinical trials the question arises as to whether this seclusion
in the academic environment is now restricting growth. The focus of
this review is to describe the status of development of cell and gene
therapies and the path to translation outside of the academic realm
and into licenced, marketable medicines.
1.2. Deﬁnitions
1.2.1. ATMPs
At present in the EU, cell and gene therapies are regulated under the
guidelines for advanced therapy medicinal products abbreviated toTarget Development  Lead optimization Produc
a. Small molecule drug development pathway 
                                              Pharma 
Academia +/Biotech  Academia 
 b. Gene and cell therapy drug development pathw
Academ
Translation Development  Produc
Academia 
Academia 
Fig. 1. a. Small molecule drug development pathway. b.‘ATMPs’. There are three categories of ATMPs, i) somatic cell therapy,
ii) gene modiﬁed cells and iii) xenotransplantation. The distinctions
are subtle, and another popular term ‘stem cell therapy’ is often used
to describe treatments that fall into either category. Occasionally treat-
ments could fall into more than one category. For instance xenotrans-
plantation of isolated cells is moving forward with the use of porcine
pancreatic islet cells for the treatment of type I diabetes [1]. In this re-
view we will focus upon the status of somatic cell therapy and the use
of gene modiﬁed cells, and aim to organise them by the ATMP
categorisation.1.2.2. Stem cell therapy
Stem cell therapies can be divided into those involving gene modi-
ﬁed cells and those not. For example: A CD34+ cell selection from
bone marrow is regarded as a haematopoietic stem cell transplantation
(HSCT) as these cells are not signiﬁcantly altered from their original
state and as such does not require an ATMP manufacturing licence. If,
however, CD34+ cells from the same source are culturedwith e.g. cyto-
kines, activating antibodies or a gene therapy vector, they becomemod-
iﬁed CD34+ cells and are regarded as an ATMP. The use of the term
‘gene therapy’ should be applied only to anATMPwhere a gene delivery
vehicle or vector is employed to generate gene modiﬁed cells.1.2.3. Cell therapy
A cell therapy ATMP is a somatic cell therapy that goes beyond the
deﬁnition of a transplant but does not involve genetic modiﬁcation of
cells. A treatment becomes a cell therapy (and an ATMP), when the
preparation involves modiﬁcation or expansion of the cells in culture.
A simple selection or enrichment of a particular group of cells from a tis-
sue does not make it an ATMP. There are now examples of stem cell
therapy, gene therapy and somatic cell therapy developments for a
wide range of tissues.tion Phase I-III Trials License & Marketing 
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Pharma / Biotech  
ay  
 
 
 
 
Commercial Entity 
Pharma / Biotech  
ia 
Pharma / Biotech  
Phase I-III Trials License & Marketing tion 
Gene and cell therapy drug development pathway.
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The progression from research and development to market of a cell
or gene therapy ATMP is not likely to follow the traditional path of a
small molecule medicine (Fig. 1a). Academic involvement continues
long after the therapy becomes a commercial entity, and in some
cases an academic consortiummay take a product all theway tomarket
(Fig. 1b). For rare diseases, this is enabled by the orphan drug designa-
tion (USA) or orphan designation (within the EU) a separate route
created to incentivise development of medicines for rare diseases by
the FDA and EMEA. A similar programme exists also in Japan.
2. Cell therapy for paediatric disease
In the UK there were 34 somatic cell therapy clinical trials open to
recruitment in the ﬁrst quarter of 2013 [2]. Here we shall introduce
the key developments for conditions affecting children.
2.1. Corneal and retinal repair
Researchers have been decoding the developmental and differentia-
tion pathway that takes embryonic stem cells (ESCs) to the functional
cell types of the eye. The aim is to use donor ESCs to replace defunct
areas of the retina and in order to improve vision in forms of blindness
involving diseased retinal tissue [3]. ESCs from the morula were chosen
as the starting cell material for cell therapy of diseased retina as they are
totipotent, that is able to differentiate into any adult cell type, and have
potentially unlimited self-renewal capacity. Transplantation of human
ESC-derived retinal pigmented epithelial cells was pioneered by oph-
thalmologists Schwartz and colleagues based at University of
California, Los Angeles, USA. The ﬁrst two patients treated were
adults with two different forms of macular degeneration, Stargardt's
disease (an inherited form of juvenile macular degeneration which
affects ~1/10,000 children) and dry age-related macular degeneration
(AMD) [4]. Retinal pigment epithelial (RPE) cells derived from embry-
onic stem cells are now being grown by Advanced Cell Technology
(ACT) as a cell therapy for Stargardt's disease. This novel cell therapy
is currently being tested in multi-centre dose ﬁnding Phase I/II clinical
trials in the Jules Stein Eye Institute, USA and at London's Moorﬁelds
Eye Institute. The FDA has awarded ACT's RPE cells orphan drug desig-
nation, which will help to make this treatment more readily available
for other patients upon completion of clinical trials.
Chemical and other types of burn injuries to the eye can result in
corneal destruction and are associated with limbal stem-cell deﬁciency.
Researchers in Milan have developed a method for ex vivo expansion
culture of autologous limbal stem cells explanted from a healthy eye
to create a larger curative patch for the treatment of limbal stem-cell de-
ﬁciency in a damaged eye [5]. The 112 patients enrolled included some
children (age range: 14–80, median: 46.5 ± 14.4 years). This cell ther-
apy requires a 1.5 × 1.5 nm explant of healthy tissue from the limbal
area to be cultured for 2–3 weeks before transplantation of the limbal
stem cell graft into an affected area. A Phase II clinical trial is also under-
way in Newcastle, UK where 7 subjects have been successfully treated
to date and orphan drug designation is sought.
Other ocular cell therapy treatments in earlier stages of develop-
ment largely atMoorﬁelds Eye Hospital NHS Foundation Trust and else-
where include photoreceptor generation from both embryonic and iPS
stem cells [6]. These are expected to impact a wide range of inherited
blindness conditions.
2.2. Pancreatic islet cell therapy
There are approximately 25,000 young persons with diabetes in
the UK and approx. 150,000 in the USA. Diabetes is typically diagnosed
between 10 and 14 years of age, and prevalence of both type I and type
II in children is rising. Approximately 10% of type I diabetes mellitus(T1DM) patients are so exquisitely sensitive to insulin that injectable re-
placements do not provide adequate or optimal management of their
blood sugar levels. Islet cell therapy is proposed as an alternative option
for this subset of patients. Cell therapy for type I diabetes received proof
of concept with the ﬁrst successful pancreatic islet transplantation in
rats in 1972 and humans in 1990 [7,8]. By 2000 Shapiro and colleagues
in Edmonton, Canada had developed an optimised cell therapy that uses
a larger dose of islet cells in conjunction with a non-glucocorticoid im-
mune suppression, consisting of anti-CD25 mAb induction, sirolimus
and low-dose tacrolimus [9]. The Edmonton protocol has now been
tested in at least 10 centres around the world and has dramatically im-
proved the insulin-independence of subjects receiving pancreatic islet
cell transplantation. Subsequent advancesmade in islet cell isolation, di-
gestion, culture and transportation strategies, which improve both yield
and longevity ex vivo and function after transplantation have improved
the 1 and 3 year outcomes. However, long term sustainability N5 years
of insulin production has not yet been achieved, likely due to acute and
chronic rejection, recurrence of autoimmunity and ongoing pharmaco-
logical damage to the graft [10].
2.3. Muscle repair
Both autologous transplantation and allo-transplantation of myo-
blasts are in development for a number of conditions including cardiac
infarction, urinal and anal incontinence and muscular dystrophy.
New myoblast-based strategies for the treatment of muscular dystro-
phy including DMD are of particular relevance for children. X-linked
Duchenne muscular dystrophy (DMD) is one of the most common and
severe muscular dystrophies with symptoms starting in early child-
hood. Phase I/II clinical trials of cell therapy using CD34+ or CD133+
autologous stem cells are beginning to show improvement of muscle
function in DMD [11]. Allo-transplantation of human umbilical cord
blood-derived mononuclear cells is also in Phase I/II trials for the treat-
ment of hereditary ataxia [12]. This is a particularly interesting venture
as the therapy is being developed with funding from the Chinese gov-
ernment at Shenhen Beike Biotechnology, China. Beike Bio. has the
most comprehensive stem cell bank in Asia and extensive GMP ATMP
stem cell facilities thus it could become the ﬁrst to manufacture
ATMPs at a sizable quantity. We will address ATMP manufacturing
quantities later.
2.4. Haematopoietic stem cell therapy adjuncts
Haematopoietic stem cell transplant (HSCT) is themainstay of treat-
ment for a wide range of childhood diseases. However patients receiv-
ing partially matched transplants are at great risk of developing graft
vs. host disease (GvHD). Patients are also at high risk of infection in
the ﬁrst 6 months following HSCT, prior to immune reconstitution by
the engrafted cells. Furthermore, previous viral infections such as CMV
may reactivate during the ﬁrst fewmonths in an immunocompromised
post-engraftment individual. Hence a number of gene and cell therapies
are in development to increase the safety of HSCT. These include both
enrichments and depletion of speciﬁc cell subsets. CD3 T cell depletion
can be employed to reduce GvHDbut at the expense of anti-viral immu-
nity. Thus Amrolia and colleagues at Baylor College of Medicine, USA
and Great Ormond Street Hospital have developed amethod for the de-
pletion of allo-reactive T cells from a HSCT before transplantation. Initial
studies had promising results with 16 patients treated. A second clinical
trial with a further reﬁned allo-depletionmethod is expected to open to
recruitment in January 2014 [13,14]. Researchers at King's College
London & Guy's & St. Thomas NHS Foundation Trust are also aiming to
reduce incidence of GvHD by an alternate method employing in vitro
expanded regulatory T cells. Their ‘NTREAT’ trial is also expected to
open soon [15]. Alternatively a CD3 depleted HSCT can be supplement-
ed by adding back only viral-speciﬁc T cells. This so called adoptive
transfer of antigen-speciﬁc donor T cells can be employed as either a
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stitution of immune responses to EBV, CMV and adenoviruses in a num-
ber of clinical trials [16–18]. Genetic modiﬁcation of cells can be
employed to generate antigen-presenting cell lines as an alternative to
antigen or peptide activation, or to further enhance this therapeutic by
generating cytotoxic T lymphocytes with speciﬁcity for multiple viruses
in a single culture [19,20]. Generation of viral-speciﬁc T cells on a per pa-
tient and typically reactive basis is costly and in some cases may be too
slow, thus a ‘cell bank’ approach has been proposed and its feasibility is
being explored [21]. In a recent multicentre trial, frozen third party
virus-speciﬁc T cells from donors with common HLA types were used
to treat 50 patients with severe EBV, CMV or adenoviral infections
post-HSCT. The results were encouraging with partial or complete
viral responses in 74% of patients, no immediate SAEs and only 2 inci-
dences of novel GvHD [22].
3. Gene therapy for paediatric disease
A gene therapy treatmentmay be ex vivo, in situ or in vivo. Ex vivo is
the route taken predominantly for gene modiﬁcation of bone marrow-
derived cells and epidermal sheets. In vivo gene therapy is when the
gene delivery vehicle is administered directly to the patient. In vivo
gene therapy might also be described as in situ e.g. inhalation of a
gene therapy vector, which is proposed for the modiﬁcation of lung ep-
ithelium. The gene delivery vehicle is normally directed at a speciﬁc cell
target. The route of administration is dictated by the location and acces-
sibility of the target cells. Theﬁrst gene therapy treatment to receive ap-
proval, alipogene tiparvovec (Glybera®) is delivered as a series of
intramuscular injections. Clinical trials are also underway with intrave-
nous injection of a gene therapy vector for haemophilia. Themajority of
gene therapy products trialled to date are ex vivo ATMPs, and of these
by far the majority are haematopoietic stem cell products but the ad-
vances made with HSCs are starting to be applied elsewhere.
3.1. Ex vivo gene therapy treatments
3.1.1. Haematopoietic stem cells (HSCs)
For this type of treatment autologous CD34+ cells are selected from
the bonemarrowor an apheresis product using standardHSCT selection
procedures. The selected cells are then cultured in a laboratory in a de-
ﬁned cell culture medium containing a cocktail of cytokines. The gene
therapy vector is added to the culture whereupon a copy of the thera-
peutic gene is introduced to the genome of the target cells. The ‘gene-
corrected’ cells are then re-administered to the patient in the form of
an ‘autologous gene modiﬁed CD34+ cell’ transplant. Great advances
have been made in the treatment of primary immune deﬁciencies and
metabolic disorders with gene therapy including X-linked severe com-
bined immunodeﬁciency (SCID), adenosine deaminase deﬁciency
(ADA), Wiskott-Aldrich syndrome (WAS) and chronic granulomatous
disease (CGD) [23,24]. The breadth of application of this technology is
expanding to include other types of hereditary conditions e.g. Fanconi
anaemia, childhood cerebral adrenoleukodystrophy (CCALD), meta-
chromatic leukodystrophies (MLDs) and X-linked lymphoproliferative
syndrome (XLP).
The ﬁrst clinical trials for gene therapy of primary immune deﬁcien-
cies used gamma retroviral (γRV) vectors. These vectors are particularly
suited to the transduction of haematopoietic cells as their structure is
derived from the genera of viruses that include HIV. Sustained immune
reconstitution was achieved with N10 year persistence of gene
corrected cells. Incidence of insertional mutagenesis through activation
of proto-oncogenes in theﬁrst clinical trials for gene therapy of X-linked
SCID was an early setback for the technology. However, the successful
disease correction and the lack of other side effects in the majority of
patients in these early trials have driven forward development of
ever safer vectors. One such improvement was the design of self-inactivating (SIN) vectorswhichhave a reduced potential for insertional
mutagenesis as a result of deletions in viral promoter elements.
The translation of gene therapy using γRV vectors was also ham-
pered by their low titre (typically 1–5 × 106 Ig/ml for GMP grade) and
dependence on actively dividing cells for effective integration. Trans-
duction protocols using γRV are laborious requiring pre-stimulation of
cells to initiate cell division, pre-loading of vector onto the surface of
cell culture containers, and multiple rounds of transduction. Improved
vectors using a lentiviral (LV) backbone were introduced to circumvent
these issues. LV vectors can be produced at much higher titre (in 2012
GMP grade LV vectors were typically supplied in the 108–109 Ig/ml
range) and enable streamlined transduction protocols. The latter further
improves safety as the decreased level of manipulation required lowers
the risk of microbiological contamination, and in the case of CD34+
stem cells, allows preservation of multi-potency. LV vectors also display
a safer integration proﬁle than their γRV counterparts and demonstrate
robust gene expression in a range of cell types [25].
Increased safety expected of SIN design vectors derived from either
γRV or LV has allowed the approval of further Phase I/II clinical trials
for X-linked SCID (SIN γRV), or SIN LV protocols for WAS, ADA and
CGD. The future may lie in alpha retroviral (αRV) vectors, which have
been shown to have a propensity for insertion in extra-genic regions
and would therefore be expected to have lower genotoxicity [26]. SIN
αRV vectors have been described and clinical trials are anticipated for
CGD [27].
ADA gene therapy appears to be the ﬁrst of the ex-vivo gene therapy
applications that is likely to make the leap into routine therapy, with a
γRV programme in development by GlaxoSmithKline in conjunction
with researchers in Milan. A Phase I/II trial for ADA with a LV vector
has recently opened in the UK & the USA and an accompanying orphan
drug designation application has been granted by MHRA.
3.1.2. Mature T cells
There are a number of therapies in development which use gene
therapy vectors to generate gene modiﬁed T cells. The early T cell
based gene therapy trials have used γRV vectors but a number of ap-
proved trials using LV vectors are currently underway. Gene modiﬁed
T cells are proposed for the treatment of cancer in several ways: a)
Generation of T cells to directly target tumour cells or b) enhancing
the safety of an allogenic bone marrow transplant (BMT).
There are two major strategies for generating tumour-speciﬁc T
cells, i) using gene therapy to generate T cells with chimeric antigen re-
ceptors (CARs) or redirected T cell receptors (TCRs) or ii) expansion of
tumour inﬁltrating lymphocytes (TIL). Autologous genetically modiﬁed
CD19 or CD30CAR+T cells are in trials for paediatric ALL and CLL,WT-1
andHBV+tumours. The success of early studies has led to a partnership
between the University of Pennsylvania and Novartis for the clinical
development of CARs, whichmay speed their progress to market. How-
ever application to childhood diseases in theUSwill be hampered by the
requirement to initially demonstrate efﬁcacy in adults. With regard to
technological progress Carl June, University of Pennsylvania, speaking
at the ESGCT Congress 2012, described progress in the ﬁeld as ‘using
CARswe can eliminate tumours but it is not yet knownhow to eradicate
them [tumours] and prevent relapses’. Early clinical trials show TIL to be
effective for melanoma, but attempts to treat cancers more commonly
occurring in children such as osteosarcoma and neuroblastoma have
so far been unsuccessful, possibly due to an anergic cytokine environ-
ment within these tumours [28]. Recent reports of serious adverse
events involving a ‘cytokine storm’ suggest the need for caution in this
area with regard to the cell dose administered and the inclusion of co-
stimulatory signalling domains [29–31].
In the context of improving the safety of allogeneic HSCT, a strategy
using genetic modiﬁcation of donor T cells to confer susceptibility to
ganciclovir has been used. The inclusion of a ‘suicide gene’ allows the
engrafted cells to be selectively targeted and deleted in the host in
cases of intractable GvHD. Alternatively EBV-speciﬁc, CMV-speciﬁc
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lected and reintroduced alongside a CD3-depeleted HSCT to enhance
anti-viral responses following chemotherapy and BMT. Clinical trials
using CMV-TCR modiﬁed allo-T cells are underway at UCL.3.1.3. Skin cells
Disruptions in the genes for keratin, collagen and laminin cause rare
but devastating skin disorders with signiﬁcant infant mortality. Col-
leagues at Great Ormond Street Hospital and Guys and St. Thomas's
Hospital NHS Trusts have taken the knowledge gained with HSC and T
cells and are moving forward directly with LV modiﬁcation in design
of clinical trials for Netherton syndrome (NS) and epidermolysis bullosa
(EB). Proof of concept was achieved with successful engraftment of
gene corrected keratinocytes in an adult patient with junctional
epidermolysis bullosa [32]. A Phase I/II trial of gene therapy for
Netherton syndrome open to children and adults is expected to start
recruiting patients in the 1st quarter of 2014, and a second trial for
epidermolysis bullosa will open later in the year. The major challenge
for gene therapy of skin sheets is the sheer size of the organ to be re-
placed. It is hoped that the introduction of skin patches secreting the
normal protein will allow spread of the secreted protein beyond the
transplanted region to allow recovery of barrier function to larger
areas of the body [33].3.2. In vivo gene therapy treatments
Adeno-associated viral (AAV) vectors have been predominantly
used as in vivo gene therapy vehicles due to their low immunogenicity
combinedwith a breadth of viral tropism that allows for entry into a va-
riety of target cells. Like LVvectors, AAV can enter both dividing and qui-
escent cells. Pseudotyping is used to ﬁne tune the infectivity of AAV
vectors.3.2.1. Metabolic disorders
Glybera® is the ﬁrst gene therapy treatment to receive an EC mar-
keting authorisation, and the ﬁrst gene therapy to be approved any-
where in the world. Glybera is a treatment for lipoprotein lipase (LPL)
deﬁciency (LPLD) an inherited condition with an incidence of ~1/
500,000 births. The majority of LPLD cases are only diagnosed in adult-
hood but symptoms are often present from the ﬁrst months of life.
Methods to diagnose LPLD are improving and a trend towards earlier di-
agnosis is expected. The LPL gene is packaged in an AAV vector which is
administered by intramuscular injection. Efﬁcacy has been demonstrat-
ed in 3 clinical trials with long-term expression of biologically active li-
poprotein lipase and a reduction in frequency of pancreatitis. Long-term
follow-up is ongoing but so far all 3 trials have had a good safety proﬁle
[34].
Other metabolic disorders have now been targeted successfully in
early phase clinical trials using HSC gene therapy with lentiviral vector
mediated gene transfer. Adrenoleukodystrophy (ALD) is a group of pro-
gressive neuropathies. Childhood cerebral ALD accounts for about 1/3 of
ALD cases and without treatment results in a vegetative state in early
childhood. BMT can be effective for this disease but carries its own
risks. Metachromatic leukodystrophy (MLD) is similarly devastating.
Without treatment children with the infantile form will die by age 5,
whilst those with juvenile MLD may survive to their early 20s or 30s.
Gene therapies for ALD andMLDare in Phase I/II trials;whilst gene ther-
apy for mucopolysaccharidoses (MPS) is currently in the preclinical
stage [35].
Intra-cranial delivery using AAV has reached clinical trials for anoth-
er leukodystrophy known as Canavans disease and also by this route
preclinical development with lentiviral vector for the treatment of
focal neocortical epilepsy is underway [36–38]. With over 40 known
leukodystrophies we can expect many more clinical trials.3.2.2. Childhood blindness
In vivo application of gene therapy is ideally suited to immune
privileged organs such as the eye. Vectors for optical conditions are
typically designed on an AAV2/2 or more recently AAV2/8 backbone.
Leber congenital amaurosis (LCA) a common form of retinal dystro-
phy is thought to account for 1/5 of cases of childhood blindness. Re-
searchers at the Moorﬁelds Eye Institute in London have a number of
therapies in the pipeline for LCA caused bymutations in retinal genes
including RPE65, AIPL1, RDH12 and RetGC-1. Gene therapies for
achromatopsia and X-linked retinitis pigmentosa (RP) are also in de-
velopment. For RP due to Prph2 gene a therapy is in development
using rAAV to deliver RNAi silencing of the damaged gene [39].
Several patients with LCA caused by mutations in RPE65 have been
enrolled in a Phase I/II study. Of 3 subjects receiving a single intraoc-
ular injection of the rAAV 2/2-hRPE65p.hRPE65, one has showed an
impressive improvement in visual acuity in low light conditions [40].
Other centres are developing gene therapy for age-related macular
degeneration, uveitis, choroideremia and diabetic eye disease. With
treatments already in progress for retinal, corneal and macular dys-
function it is likely that many structures within the eye can one day
be treated with some form of cell therapy. Together these form a re-
markable leap forward in the prognosis for inherited and acquired
causes of blindness.
3.2.3. Haemophilia
Gene therapy has been proposed as a treatment for haemophilia for
many years. The ﬁrst attempts to treat either haemophilia A or B either
failed to generate persistent protein expression and had immune-
mediated toxicity or had only transient protein expression due to
immune-mediated deletion of transduced cells [41]. A number of strat-
egies to reﬁne gene therapy for haemophilia are currently being inves-
tigated notably a switch to the use of AAV8 serotype vectors, and
subsequentmodiﬁcations to vector design such as i) increasing the spe-
ciﬁc activity of the factor IX (FIX) expressed by introduction of
favourable sequence variants and ii) improved manufacture methods
to reduce the level of empty capsids and hence the immunogenic load.
There are currently 3 actively recruiting trials of gene therapy for FIX
listed on clinicaltrials.gov. Early reports from one of these, amulticentre
gene therapy trial using an AAV for the expression of factor IX for
haemophilia B, recruiting at University College London Hospital,
Stanford Medical School and St. Jude Children's Research Hospital are
reporting great success in adults. If sufﬁcient safety and efﬁcacy are
demonstrated, we can expect recruitment to be expanded to include ju-
veniles in the near future and further trials speciﬁcally for children [42]
and personal communication. Successes in gene-mediated correction of
factor IX deﬁciency can be expected to accelerate development of strat-
egies for factor VIII and haemophilia A.
3.3. Non-viral vector delivery systems
3.3.1. Respiratory disorders
Cystic ﬁbrosis (CF) is a severe, life limiting condition, characterised
by viscous secretions, scarring and cysts in the lungs, pancreas, liver
and intestines. Most cases manifest in the ﬁrst year of life and CF has
an incidence of 1:2,000–15,000 worldwide. The causative CFTR gene
was identiﬁed in the 1980s and disease causing mutations are carried
by approx. 1/30 of the western population. The challenge in targeting
CFTR mutations is in their location. The affected cells are structural so
BMT is not applicable. Gene therapy to treat the respiratory aspects of
the disease with an inhaled vector is appealing but any gene therapy
agent will require repeated applications in a mucous-ﬁlled hostile envi-
ronment. Viral vectors are not suitable for repeated application thus a
CFTR-expressing plasmid complexed with a cationic lipid ‘nanoparticle’
has been developed and is currently being tested in clinical trials. Over
70 patients have now received at least one dose of gene therapy in the
Table 1
What common technological advances are most needed to deliver ATMPs as routine
medicines worldwide?
✓ More efﬁcient bulk production of GMP grade vectors and animal-free cell culture
media
✓ Flexible, high capacity, automated systems for cell selection, cell culture and gene
transduction
✓ Improved low weight vialling precision to:
o enable dispensing of lyophilised vector doses for in vivo administration
without additional QA review
o improve ex vivo manufacturing consistency when using lyophilised raw
materials
✓ Greater and more stable quantities of starting cells — iPS may enable this.
✓ Transportation solutions for distribution of fragile, temperature sensitive cell
products over large distances:
o Improved cryopreservation and hypothermic preservation media
o Sterile packaging for transportation of 2D and 3D cell cultures
o Logistics & importation restrictions— can we adapt the BMT/organ
transplantation models?
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at 2 sites in the UK [43].
3.3.2. Muscular dystrophies
A number of gene therapy approaches are in development for
Duchennemuscular dystrophy (DMD). There are two notable commer-
cial enterprises one led byGSK the other by Sarepta. Both are employing
anti-sense oligonucleotides to target exon 51 and both have progressed
to Phase IIB–III clinical trials. Development of therapies targeting other
exons, particularly exon 53, are still needed to make therapy available
for all types of DMD. Improved methods of tissue targeting are needed
to restore dystrophin in all tissues and may be provided by peptide-
conjugated oligonucleotides. The progress of gene therapy development
for DMD has been comprehensively reviewed by Benedetti [44].
4. Driving gene and cell therapy medicines forward
4.1. The ATMP development pathway
The progression from R&D to clinical trial is expedited for cell and
gene therapies compared to traditional medicines i.e. small molecule,
antibodies and vaccines. ATMPs are often personalised medicines
where Phase I safety testing in healthy human volunteers is neither ap-
propriate nor relevant. Furthermore the randomised double-blinded
placebo-controlled Phase III trial, the benchmark of traditional small
molecule development, is not feasible for ATMPs especially as many
are in the ﬁeld of rare diseases. One cannot have a placebo for a skin
graft or a stem cell transplant. There are too few patients to randomiseTable 2
What are the key questions to consider early in development of gene/cell therapy for efﬁcient
• What IS the ﬁnal ATMP product? • Gene modiﬁed cells? The vector? The
• What will be the ﬁnal formulation of the
ATMP?
• Fresh? Frozen? Cell suspension? Lyop
• Single or multiple doses per manufact
• What are theminimumquality speciﬁcation(s)? • Number of cells? Size? Viability? Tran
• Will the QC results be available before
• Can your R&D production method be scaled up? • Cell ﬂasks vs. cell factories
• Availability of GMP grade raw materia
• Automated aseptic processing e.g. sep
• What is the national/international manufactur-
ing strategy
i.e. hubs vs. single manufacturing centre?
• Need to consider the robustness of th
ATMP or the patient?
• Will the patient need to return to the
Special considerations for autologous products:
• Is there a holding therapy between harvest and
return?
• Where there is a holding therapy (e.g
products. e.g. transduce the cells, freez
administer the product
• What if the product fails QA review? • Can the raw material collection be rep
• What is the alternative therapy for thinto different treatment arms, and ‘blinding’ of participants and their cli-
nicians is impractical if not impossible. Thus many of the clinical trials
reported are Phase I/II studies where proof of both efﬁcacy and safety
is sought. From a successful Phase II study, the possibility exists for pro-
gression to licensing and marketing authorisation. However, this next
phase is hampered by the availability of cell culture facilities and in
most cases the lack of technology to manufacture at scale sufﬁcient for
national or international supply. A number of technological advances
are desperately needed to advance the whole ﬁeld towards large scale,
multi-national distribution (summarised in Table 1). To date, although
several have received orphan drug designation only 4 ATMPs have re-
ceived marketing authorisations: Glybera, Epicel, Carticel and
ChrondroCelect. Despite the 20 years of clinical trials there is only one
licenced gene therapy treatment, Glybera. The slow rate of progress
has been acknowledged and a tide change is forecast. Political objec-
tions to stem cell research in the USA have declined in recent years. In
2012 a UK government funded body, called cell therapy catapult, was
established with the aim to accelerate commercialisation of cell therapy
technology.
It seems that a gene or cell therapy ‘ﬁx’ can now be envisioned for a
large number of inherited and acquired disease. However, for this vision
to reach fruition the businessmodel formanufacture of ATMPs has to be
different from traditional pharmaceutical manufacturing. Cell products
have short expiry and require unusual transport conditions compared
to a traditional medicine. Batch manufacture is often replaced by inde-
pendent manufacture runs of a single personalised product and with
this comes signiﬁcant individual variation of each preparation. The key
to rapid translation from research to therapy is an understanding of
the GMP process from the beginning (see Table 2), and as ever, access
to appropriate resources (summarised in Tables 3 and 4). At present
the ﬁeld remains at a very early stage and the models for true
commercialisation are yet to be established.
4.2. Cost vs. beneﬁt?
In themajority of cases cell and gene therapies represent good value
compared to conventional treatments. For instance, in the UK limbal
stem cell therapy costs an average of £3,000/subject whereas a conven-
tional corneal transplant is billed at £6,000. The latter would also re-
quire more signiﬁcant aftercare to reduce and GvHD, thus an
autologous limbal stem cell therapy has potential to be doubly econom-
ical. Likewise an allogeneic bonemarrow transplant for a patient with a
primary immunodeﬁciency costs typically £250,000 and upwards,
given the cost of inpatient stay, drugs and frequency of complications
such as GvHD. In contrast, manufacture of autologous gene modiﬁed
CD34+ cells can be achieved for approx. £15,000–30,000. The addition-
al follow-up costs of gene therapy treatment for primary immunetranslation later?
cell sheet?
hilised vector?
ure?
sduction efﬁciency?
the treatment is administered?
ls
ax, COBE, cliniMACS, WAVE, prodigy
e ATMP for transportation, i.e. is it preferable to transport the
manufacturing centre for follow-up and monitoring tests?
. enzyme replacement) it is simpler to control the quality of autologous
e the product, check the quality i.e. transduction efﬁciency and sterility, then defrost and
eated?
e patient?
Table 3
What are the key requirements to deliver a gene therapy service?
• MHRA licenced GMP manufacturing facility I.e. ‘clean room’ min. 30 m2
• Contract with MHRA Qualiﬁed Person as named on that licence E.g. 1 or more QPs employed as a consultant
• Co-ordination and preferably co-localisation of cell harvest, manipulation and cell culture
laboratory facilities
E.g. ward/theatre, CD34+ cell selection lab & clean room on the same campus
• GMP grade (animal free) raw materials EMEA or FDA GMP licenced suppliers
• Adequate appropriate cell source for therapy AND for validation of manufacturing methods Validations need to be of a similar scale to the actual therapy
• Laboratories for microbiological, protein and genetic analysis E.g. hospital diagnostics laboratories
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hospital stay, long-term prophylactic medication requirements and
other post-therapy complications are considerably reduced compared
to conventional BMT. GMPmanufacturing costs for the ATMPs currently
in clinical trials at Great Ormond Street Hospital are broken down into
vector procurement costs of £5,000–15,000 per trial participant, largely
dependent on the individual's age/bodymass; plus aseptic manufacture
costs typically £10,000 ± £3,000 per patient per product, the range
being dependent upon the number of days of culture required and the
complexity of the gene transfer process.
The extreme specialisation of cell and gene therapies brings many
unusual and often costly implications. A unique challenge in rare genet-
ic disorders is in the youth of the paediatric patient. National and private
healthcare rarely provides for the needs of the accompanying family
members. Portability of anATMP vs. transportation of the infant or juve-
nile patient to the manufacture site is an important factor for consider-
ation in the design of a clinical trial. Trial sponsors should also consider
whether there is a practical distribution strategy for the marketed
product. This and other key factors to consider for efﬁcient translation
from research to routine therapy are described in Table 2.
Cost effective ATMP development for rare diseases is enabled by the
orphan drug designationwhich offersmarket exclusivity once a product
has marketing authorisation. The challenge to other emerging markets
such as South and Central American countries is to forge links and
form similar pan-continental regulatory frameworks. We would en-
courage an approach that mirrors either the FDA or EMEA to pave the
way for the simplest international collaborations, multi-centre studies
and eventually world-wide licencing.
Finally, of course the foremost question of cost versus beneﬁt in the
minds of patients, their families and their doctors is the potential for
therapeutic beneﬁt versus signiﬁcant risk to life and/or quality of life.
The ability to self-medicate, attend school, and associate with peers
are key issues for childrenwith disease and impact greatly on their qual-
ity of life. Thus curative treatment can have substantial quality of life
beneﬁt over life-long medication. The majority of ATMPs discussed
above offer a real prospect of curative treatment but with equally real
possibilities of malignancy, infection or other toxicities. Therefore the
ultimate answer to this question is extremely individual and will onlyTable 4
What are the practicalities of a GMP cell therapy manufacturing facility?
• Infrastructure— sponsoring institution, laboratories, ofﬁces, archive facilities
• Laboratory — with biological safety cabinets, isolators, signiﬁcant air handling,
staged changing areas
• Locked dedicated materials storage areas
• Real-time electronic monitoring of all the above facilities and equipment
• Regular preventativemaintenance
• Dedicated daily cleaning
• Weekly and in-session microbiological environmental monitoring
• Quality assurance of equipment, assays and manufacturing method
• Traceability of all raw materials, and their method of manufacture
• A team of highly trained personnel— each step requires an ‘operator’ and a
‘checker’, each process requires QA review and QP release, hence a minimum
of 3 manufacturing staff, plus a QA and a part-time QP
• Quality management system and extensive documentation for GCP & GMP
• Continuous corrective and preventative action (CAPA)
• Initial ATMP licence application and annual/bi-annual MHRA auditingbe found in time and with the conduct of carefully regulated fully in-
formed clinical studies.References
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